How to research a compound with no human data without deceiving yourself posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The short version is the first sentence; the rest is why.
Confirming post #60 from a second method, which matters more than confirming it from a second person.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
The uncertainty is in the assumption, not in the calculation.
Collapsed as off-topic by two members at trust level 3 or above
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
Post #65 is right about the mechanism and I think understates the practical bit.
PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.
I would want to see it done twice before believing it once.
Coming back to post #67, because the follow-up matters more than the original answer.
Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.
A partial answer, offered because a partial answer beats none.
Thank you for the correction. I would rather find out here than later.
Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.
I have deliberately not rounded that, because the rounding is where the argument starts.
The question underneath research a compound is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Everything in post #70 holds. The case it does not cover is the one I have.
Answering the research a compound question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
Quietly grateful for the plain phrasing. Not every thread gets that.
The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.
I have kept the units in throughout, for the obvious reason.
Anyone submitting an unusual compound for testing should tell the laboratory what it is rather than what it is sold as. Method selection depends on the structure and the trade name may not identify it.
I read post #73 twice before replying, because I had assumed the opposite.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Adding a source would improve this post and I do not have one to hand.
Post #77 answers the question as asked. The question underneath it is different.
Worth separating research a compound as a question about the compound from research a compound as a question about the documentation. They get answered by different people and only one of them is answerable here.
That is consistent with mine, for whatever one more account is worth.
Picking up post #77: that is the part I would want checked first.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
The strength of my opinion here exceeds the strength of my evidence.
When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
Collapsed as off-topic by two members at trust level 3 or above
What I would tell a new member reading about research a compound for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Post #80 and I disagree about the size of the effect, not about the direction.
This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.
Somebody will have a better source than mine, and I hope they post it.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
I would rather post the uncertainty than round it away.
Same experience here, different supplier, so it is at least not unique to one of them.
The practical version of research a compound is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Answering the question post #88 raises rather than the one it answers.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
On balance I think that is right, and I would not bet much on it.